FDAnews Drug Daily Bulletin
Pharmaceuticals / Inspections and Audits

Three-Drug Combination Extends Multiple Myeloma Survival to Six Years in Phase III Trial

Jan. 11, 2017

A Phase III trial found that a three-drug combination — adding bortezomib to the standard therapy of lenalidomide and dexamethasone — extended multiple myeloma remissions by one year and added another year of survival, compared to the two-drug therapy alone.

Researchers found that patients who received the bortezomib combination lived a median of 75 months after their initial six-month treatment. The study was sponsored by the International Myeloma Foundation and SWOG, a publically funded trials network. The results were published in The Lancet.

Lenalidomide is an immunomodulating therapy marketed as Revlimid by Celgene. Bortezomib is a proteasome inhibitor marketed as Velcade by Millennium Pharmaceuticals.

View today's stories